RETROSPECTIVE OF OVER A DECADE OF ECONOMIC ASSESSMENT: UPDATE ON FRENCH ECONOMIC AND PUBLIC HEALTH EVALUATION COMMITTEE ACTIVITY (2014-2025)
Author(s)
Noemie Pouxviel, Pharm D, Laetitia Rey, PharmD, Chloe Gerves-Pinquie, PhD.
IQVIA, Paris, France.
IQVIA, Paris, France.
OBJECTIVES: Since the introduction of health economic assessment in France in 2014, the Economic and Public Health Evaluation Committee (CEESP) has issued numerous opinions on cost-effectiveness and budget impact of health products. This study provides an 11-year retrospective analysis of CEESP activity, focusing on methodologies, outcomes, and evolving evaluation practices.
METHODS: Data were extracted from IQVIA’s internal exhaustive database covering CEESP opinions published between 2014 and 2025. Analyses included the number and type of evaluations, therapeutic areas, appraisal timelines, integration of organizational impact, and a detailed review of methodological reservations and global major uncertainties according to CEESP doctrine.
RESULTS: Since 2014, CEESP has published 254 opinions, averaging 21 per year, predominantly on medicines and vaccines (86%). A downward trend has been observed since 2023, reflecting stricter eligibility criteria. Most submissions included cost-effectiveness and cost-utility analyses, with budget impact analyses increasingly incorporated over time. Between 2014 and 2024, half of analyses were invalidated, mainly due to modeling choices (42%), utility measurement and valuation (19%), and structural assumptions (17%). In contrast, only 7% were invalidated in 2025, with no global major uncertainty reported. Since 2020, an increasing number of submissions have claimed organizational impact, primarily related to healthcare organization, professional practices, and patient management; however, such claims remain limited overall. For validated analyses, the median ICER was €135,570/QALY, with substantial variability across therapeutic areas, particularly in rare diseases. Appraisal timelines increased from 2021 to 6.7 months, before decreasing to 5.5 months in 2025.
CONCLUSIONS: Budget impact analysis is increasingly used in CEESP submissions, while the number of evaluations continues to decline. Organizational impact remains underexploited. Improvements observed in 2025 may reflect changes in submission characteristics, including lower submission volume and less complex evidence packages, rather than structural changes in appraisal practices.
METHODS: Data were extracted from IQVIA’s internal exhaustive database covering CEESP opinions published between 2014 and 2025. Analyses included the number and type of evaluations, therapeutic areas, appraisal timelines, integration of organizational impact, and a detailed review of methodological reservations and global major uncertainties according to CEESP doctrine.
RESULTS: Since 2014, CEESP has published 254 opinions, averaging 21 per year, predominantly on medicines and vaccines (86%). A downward trend has been observed since 2023, reflecting stricter eligibility criteria. Most submissions included cost-effectiveness and cost-utility analyses, with budget impact analyses increasingly incorporated over time. Between 2014 and 2024, half of analyses were invalidated, mainly due to modeling choices (42%), utility measurement and valuation (19%), and structural assumptions (17%). In contrast, only 7% were invalidated in 2025, with no global major uncertainty reported. Since 2020, an increasing number of submissions have claimed organizational impact, primarily related to healthcare organization, professional practices, and patient management; however, such claims remain limited overall. For validated analyses, the median ICER was €135,570/QALY, with substantial variability across therapeutic areas, particularly in rare diseases. Appraisal timelines increased from 2021 to 6.7 months, before decreasing to 5.5 months in 2025.
CONCLUSIONS: Budget impact analysis is increasingly used in CEESP submissions, while the number of evaluations continues to decline. Organizational impact remains underexploited. Improvements observed in 2025 may reflect changes in submission characteristics, including lower submission volume and less complex evidence packages, rather than structural changes in appraisal practices.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HTA212
Topic
Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes, Value Frameworks & Dossier Format
Disease
No Additional Disease & Conditions/Specialized Treatment Areas